Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results

ABSTRACT Purpose: This study was conducted to evaluate visual function and changes in the central macular thickness of patients with unresponsive neovascular age-related macular degeneration who were switched from ranibizumab (Lucentis®) to aflibercept (Eylea®) treatment at 30 months. Methods: This...

ver descrição completa

Detalhes bibliográficos
Autor principal: Ertan,Elif (author)
Outros Autores: Doğan,Mustafa (author), Polat,Onur (author), Efe,Neriman (author), Akdoğan,Müberra (author), İnan,Sibel (author), Duman,Reşat (author), Duman,Rahmi (author)
Formato: article
Idioma:eng
Publicado em: 2021
Assuntos:
Macular degeneration
Ranibizumab/therapeutic use
Angiogenesis inhibitors/therapeutic use
Intravitreal injections
Retina/pathology
Visual acuity
Texto completo:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492021000300225
País:Brasil
Oai:oai:scielo:S0004-27492021000300225

Texto Completo

http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492021000300225

Registos relacionados